Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) traded down 2% during trading on Monday . The stock traded as low as $33.87 and last traded at $33.92, with a volume of 1,456,817 shares. The stock had previously closed at $34.62.

Several analysts have recently commented on the company. Vetr downgraded Acadia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.04 price objective for the company. in a research note on Monday, June 6th. Bank of America Corp. lowered Acadia Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $40.00 target price for the company. in a report on Wednesday, June 22nd. They noted that the move was a valuation call. Leerink Swann reaffirmed a “hold” rating on shares of Acadia Pharmaceuticals in a report on Sunday, May 22nd. Cowen and Company reaffirmed a “buy” rating on shares of Acadia Pharmaceuticals in a report on Sunday, April 17th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $44.00 target price on shares of Acadia Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $46.20.

The stock’s market capitalization is $3.84 billion. The firm’s 50-day moving average is $35.67 and its 200 day moving average is $28.29.

Acadia Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.03. During the same period in the prior year, the company earned ($0.40) EPS. On average, equities research analysts predict that Acadia Pharmaceuticals Inc. will post ($1.70) EPS for the current year.

In other Acadia Pharmaceuticals news, Director Leslie L. Iversen sold 33,697 shares of the stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $33.53, for a total transaction of $1,129,860.41. Following the completion of the transaction, the director now owns 69,824 shares of the company’s stock, valued at approximately $2,341,198.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several hedge funds and institutional investors recently added to or reduced their stakes in the stock. Eagle Asset Management bought a new position in Acadia Pharmaceuticals during the third quarter valued at approximately $40,764,000. Nationwide Fund Advisors increased its position in Acadia Pharmaceuticals by 29.8% in the fourth quarter. Nationwide Fund Advisors now owns 66,643 shares of the biopharmaceutical company’s stock valued at $2,376,000 after buying an additional 15,282 shares during the period. Rhumbline Advisers increased its position in Acadia Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 74,690 shares of the biopharmaceutical company’s stock valued at $2,663,000 after buying an additional 1,715 shares during the period. California Public Employees Retirement System increased its position in Acadia Pharmaceuticals by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 194,000 shares of the biopharmaceutical company’s stock valued at $6,916,000 after buying an additional 900 shares during the period. Finally, Columbus Circle Investors bought a new position in Acadia Pharmaceuticals during the fourth quarter valued at approximately $1,376,000.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.